Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 7, 2013, Pages 630-645

  Gremmel, Thomas ^a   Perkmann, Thomas ^a   Seidinger, Daniela ^a   Koppensteiner, Renate ^a   Panzer, Simon ^a   Kopp, Christoph W ^a   Steiner, Sabine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aspirin; Inflammation; Platelet reactivity; Thromboxane B2

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; PROTON PUMP INHIBITOR; THROMBOXANE B2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOASSAY; INFLAMMATION; LABORATORY TEST; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ELECTRODE AGGREGOMETRY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; RISK; SHEAR STRESS; SMOKING; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; URINALYSIS;

EID: 84880928455     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.17665     Document Type: Article

References (46)

1. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C: Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med, 2005; 353: 2373-2383
2. Patrono C, Rocca B: Aspirin, 110 years later. J Thromb Haemost, 2009; 7 Suppl 1: 258-261
3. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 1971; 231: 232-235
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj, 2002; 324: 71-86
5. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009; 373: 1849-1860
6. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK: Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost, 2005; 3: 1309-1311
7. Cattaneo M: Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol, 2004; 24: 1980-1987
8. Cattaneo M: Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J, 2007; 28: 1673-1675
9. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW: Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets, 2011; 22: 188-195
10. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J, 2007; 28: 1702-1708
11. Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD: A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost, 2010; 103: 1245-1253
12. Szczeklik A, Musial J, Undas A, Sanak M: Aspirin resistance. J Thromb Haemost, 2005; 3: 1655-1662
13. Fitzgerald R, Pirmohamed M: Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacology & therapeutics, 2011; 130: 213-225
14. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 2001; 345: 1809-1817
15. Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G, Nicolucci A: Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost, 2005; 93: 8-16
16. Watala C, Boncler M, Gresner P: Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacological reports: PR, 2005; 57 Suppl: 42-58
17. Scheen AJ, Legrand D: Aspirin and clopidogrel resistance in patients with diabetes mellitus. Eur Heart J, 2006; 27: 2900; author reply 2900-2901
18. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davi G, Cuccurullo F, Patrono C: Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation, 2000; 102: 1007-1013
19. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000; 342: 836-843
20. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men: N Engl J Med, 1997; 336: 973-979
21. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol, 2003; 41: 961-965
22. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2002; 105: 1650-1655
23. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KA, Topol EJ: Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation, 2008; 118: 1705-1712
24. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP: Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med, 2007; 120: 631-635
25. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol, 2004; 43: 1122-1126
26. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM: High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost, 2010; 8: 2140-2148
27. Poulsen TS, Mickley H: Is the antiplatelet effect of aspirin affected by systemic inflammation? Ann Hematol, 2004; 83: 728
28. Hamwi A, Vukovich T, Wagner O, Rumpold H, Spies R, Stich M, Langecker C: Evaluation of turbidimetric highsensitivity C-reactive protein assays for cardiovascular risk estimation. Clin Chem, 2001; 47: 2044-2046
29. Muir AR, McMullin MF, Patterson C, McKeown PP: Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart, 2009; 95: 1225-1229
30. Linnemann B, Schwonberg J, Mani H, Prochnow S, Lindhoff-Last E: Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost, 2008; 6: 677-683
31. Cattaneo M, Lecchi A, Zighetti ML, Lussana F: Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica, 2007; 92: 694-697
32. Shenkman B, Matetzky S, Fefer P, Hod H, Einav Y, Lubetsky A, Varon D, Savion N: Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. Thromb Res, 2008; 122: 336-345
33. Fritsma GA, Ens GE, Alvord MA, Carroll AA, Jensen R: Monitoring the antiplatelet action of aspirin. JAAPA: official journal of the American Academy of Physician Assistants, 2001; 14: 57-58
34. Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ: Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol, 2000; 165: 1605-1611
35. Maloney CG, Thompson SD, Hill HR, Bohnsack JF, McIntyre TM, Zimmerman GA: Induction of cyclooxygenase- 2 by human monocytes exposed to group B strep tococci. J Leukoc Biol, 2000; 67: 615-621
36. Zaitsu M, Hamasaki Y, Nishimura S, Matsuo M, Fujita I, Ishii E: Thromboxane synthesis is increased by upregulation of cytosolic phospholipase A2 and cyclooxygenase-2 in peripheral polymorphonuclear leukocytes during bacterial infection in childhood. Am J Hematol, 2003; 72: 115-120
37. Siller-Matula JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, Huber K, Tolios A, Drucker C, Jilma B: Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated nonresponsiveness to clopidogrel or aspirin. Int J Cardiol, 2012; ahead of print
38. Spectre G, Mosseri M, Abdelrahman NM, Briskin E, Bulut A, Loncar S, Varon D, Alcalai R: Clinical and prognostic implications of the initial response to aspirin in patients with acute coronary syndrome. Am J Cardiol, 2011; 108: 1112-1118
39. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA: Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res, 1980; 17: 317-327
40. Helft G, Osende JI, Worthley SG, Zaman AG, Rodriguez OJ, Lev EI, Farkouh ME, Fuster V, Badimon JJ, Chesebro JH: Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol, 2000; 20: 2316-2321
41. Siller-Matula JM, Haberl K, Prillinger K, Panzer S, Lang I, Jilma B: The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res, 2009; 123: 874-880.
42. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD: Aspirin 'resistance': role of preexistent platelet reactivity and correlation between tests. J Thromb Haemost, 2008; 6: 2035-2044
43. Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schomig A, Kastrati A, Sibbing D: Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost, 2010; 104: 1193-1200
44. Muller K, Aichele S, Herkommer M, Bigalke B, Stellos K, Htun P, Fateh-Moghadam S, May AE, Flather M, Gawaz M, Geisler T: Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis, 2010; 213: 256-262
45. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW: The influencing factors for clopidogrel- mediated platelet inhibition are assay-dependent. Thromb Res, 2011; 128: 352-357
46. Hwang SJ, Park KW, Kwon DA, Kang HJ, Koo BK, Chae IH, Gwon HC, Park SJ, Seung KB, Ahn T, Yoon JH, Jang YS, Jeong MH, Tahk SJ, Kim HS, Korea Stent Thrombosis I: High plasma interleukin-6 is associated with drugeluting stent thrombosis: possible role of inflammatory cytokines in the development of stent thrombosis from the Korea Stent Thrombosis Registry. Circ J, 2011; 75: 1350-1357